Dear GlaxoSmithKline plc (ADR) (GSK): Here’s An Apology

Page 2 of 2

Sooooo Glaxo
I may have been bitter about GlaxoSmithKline plc (ADR) (GSK) (NYSE:GSK), but I wasn’t twisted enough to actually sell it. Even good companies go through bad times, and Glaxo was always too big and too clever to struggle for long. I had always seen it as a long-term hold, rather than a short-term panic and sell. So I have nothing to apologise for there. Yet, I wouldn’t rush to buy Glaxo now. It trades at 14.9 times earnings, which suggests it is pretty fairly valued. The time to buy was back in January, when one journalist was cheeky enough to label it one of the worst five stocks on the FTSE 100 (INDEXFTSE:UKX).

The article To GlaxoSmithKline, an Apology originally appeared on Fool.com is written by Harvey Jones.

Harvey Jones has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Page 2 of 2